(Short communication) In vitro Tumorigenicity Assessment of Mesenchymal Stem/Stromal Cells Using the Soft Agar Colony Formation Assay
Keywords:
Mesenchymal stem cells, Soft agar colony formation assay, Tumorigenicity, Anchorage-independent growthAbstract
The in vitro expansion of mesenchymal stem/stromal cells (MSCs) for clinical research and therapeutic applications requires stringent quality and safety assessment, particularly regarding the risk of tumorigenicity following long-term culture. This study aimed to evaluate the suitability of the soft agar colony formation assay as a tool for monitoring tumorigenic potential and quality control of MSCs during in vitro expansion. The assay was performed using a two-layer agar system (0.6% base agar and 0.4% cell agar) with cells cultured for 11 days. MSCs at passages 7-9 derived from three different sources, including bone marrow (BM-MSCs, n = 1), amniotic fluid (AF-MSCs, n = 3), and Wharton’s jelly (WJ-MSCs, n = 3), were compared with positive control cells (CHL cells) and a negative control (No cell). Colony formation was qualitatively evaluated under an inverted microscope and quantitatively assessed by measuring relative fluorescence units (RFU) using CyQuant® GR dye. The results demonstrated that the assay effectively distinguished anchorage-independent growth characteristics. Positive control cells formed distinct colonies and exhibited significantly higher RFU values than all MSC groups (p < 0.05). In contrast, MSCs from all three sources showed no detectable colony formation and maintained low RFU levels comparable to the negative control group, indicating no evidence of in vitro tumorigenic properties at the tested passages. These findings suggest that the soft agar colony formation assay is suitable for supporting the assessment of MSC tumorigenicity at the tested passages and may be incorporated as part of routine quality control together with other safety assessments prior to clinical use.
References
1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
2. Dzobo K. Recent trends in multipotent human mesenchymal stem/stromal cells: Learning from history and advancing clinical applications. OMICS 2021; 25: 342-57.
3. Yang G, Fan X, Liu Y, et al. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep 2023; 19: 1214-31.
4. Alvites R, Branquinho M, Sousa AC, et al. Mesenchymal stem/stromal Cells and their paracrine activity-immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics 2022; 14: 381.
5. Galipeau J, Sensébé L. Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell 2018; 22: 824-33.
6. Pakzad M, Hassani SN, Abbasi F, et al. A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications. Stem Cell Rev Rep 2022; 18: 2279-95.
7. Montemurro T, Lavazza C, Montelatici E, et al. Off-the-Shelf Cord-Blood Mesenchymal Stromal Cells: Production, Quality Control, and Clinical Use. Cells 2024; 13: 1066.
8. Phermthai T, Thongbopit S, Wataganara T, et al. Clinical-grade allogeneic amniotic fluid stem cell banking: quality control for therapeutic applications and drug development. Stem Cell Res Ther 2025; 16: 509.
9. Partan RU, Putra KM, Kusuma NF, et al. Umbilical cord mesenchymal stem cell secretome improves clinical outcomes and changes biomarkers in knee osteoarthritis. J Clin Med 2023; 12: 7138.
10. Bolandnazar NS, Raeissadat SA, Haghighatkhah H, et al. Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial. BMC Musculoskelet Disord 2024; 25: 856.
11. Xie X, Song Q, Dai C, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial. Gen Psychiatr 2023; 36: e101143.
12. Tonti GA, Mannello F. From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol 2008; 52: 1023-32.
13. Kim M, Rhee JK, Choi H, et al. Passage-dependent accumulation of somatic mutations in mesenchymal stromal cells during in vitro culture revealed by whole genome sequencing. Sci Rep 2017; 7: 14508.
14. Neri S. Genetic Stability of Mesenchymal Stromal Cells for Regenerative Medicine Applications: A Fundamental Biosafety Aspect. Int J Mol Sci 2019; 20: 2406.
15. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-53.
16. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001.
17. Berkowitz AL, Miller MB, Mir SA, et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”. N Engl J Med 2016; 375: 196-8.
18. Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. N Engl J Med 2018; 378: 954-9.
19. U.S. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine [Internet]. 2017 [cited 2026 May 11]. Available from: https://www.fda. gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fdas-new-policy-steps-and-enforcement-efforts-ensure.
20. Rebelatto CLK, Boldrini-Leite LM, Daga DR, et al. Quality control optimization for minimizing security risks associated with mesenchymal stromal cell-based product development. Int J Mol Sci 2023; 24: 12955.
21. Pochampally R. Colony forming unit assays for MSCs. Methods Mol Biol 2008; 449: 83-91.
22. Rotem A, Janzer A, Izar B, et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc Natl Acad Sci U S A 2015; 112: 5708-13.
23. Wang Z. Assessing tumorigenicity in stem cell-derived therapeutic products: a critical step in safeguarding regenerative medicine. Bioengineering 2023; 10: 857.
24. Nakamura D. The evaluation of tumorigenicity and characterization of colonies in a soft agar colony formation assay using polymerase chain reaction. Sci Rep 2023; 13: 5405.
25. Meza-Zepeda LA, Noer A, Dahl JA, et al. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 2008; 12: 553-63.
26. Wang Y, Zhang Z, Chi Y, et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. Cell Death Dis 2013; 4: e950.
27. Chin SP, Saffery NS, Then KY, et al. Preclinical assessments of safety and tumorigenicity of very high doses of allogeneic human umbilical cord mesenchymal stem cells. In Vitro Cell Dev Biol Anim 2024; 60: 307-19.
28. Kusakawa S, Yasuda S, Kuroda T, et al. Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation. Sci Rep 2015; 5: 17892.
29. Bando K, Kusakawa S, Adachi H, et al. Protocol improvement and multisite validation of a digital soft agar colony formation assay for tumorigenic transformed cells intermingled in cell therapy products. Cytotherapy 2024; 26: 769-77.
30. Zinöcker S, Wang MY, Gaustad P, et al. Mycoplasma contamination revisited: mesenchymal stromal cells harboring Mycoplasma hyorhinis potently inhibit lymphocyte proliferation in vitro. PLoS One 2011; 6: e16005.
31. Torsvik A, Røsland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track—letter. Cancer Res 2010; 70: 6393-6.
32. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3: e2213.
33. Neri S, Bartolotti I, Pedrini E, et al. Human adipose-derived mesenchymal stromal cells in vitro expansion for regenerative applications: tracking small genetic variants reveals dynamic changes within a genetically stable framework. Stem Cell Res Ther 2026; 17: 258.
34. Leonov GE, Grinchevskaya LR, Makhnach OV, et al. Safety assessment of stem cell-based therapies: current standards and advancing frameworks. Cells 2025; 14: 1660.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of the Medical Technologist Association of Thailand

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.